183 related articles for article (PubMed ID: 26479990)
1. Use of Vandetanib in Metastatic Medullary Carcinoma of Thyroid in a Pediatric Patient With Multiple Endocrine Neoplasia 2B.
Narayanan VK; Ronghe M; MacGregor FB; Bradshaw N; Davidson R; Welbury R; Reed N; Shaikh MG
J Pediatr Hematol Oncol; 2016 Mar; 38(2):155-7. PubMed ID: 26479990
[TBL] [Abstract][Full Text] [Related]
2. Pregnancy on vandetanib in metastatic medullary thyroid carcinoma associated with multiple endocrine neoplasia type 2B.
Thomas N; Glod J; Derse-Anthony C; Baple EL; Osborne N; Sturley R; Vaidya B; Newbold K; Brooke A
Clin Endocrinol (Oxf); 2018 May; 88(5):754-756. PubMed ID: 29457255
[No Abstract] [Full Text] [Related]
3. Vandetanib Tumor Shrinkage in Metastatic Medullary Thyroid Cancer Allowing Surgical Resection of the Primary Site: A Case Report.
Milner TD; Ronghe M; Shaikh MG; MacGregor FB; Reed N
J Pediatr Hematol Oncol; 2019 Jul; 41(5):e329-e332. PubMed ID: 30334899
[TBL] [Abstract][Full Text] [Related]
4. [Metastatic medullary thyroid carcinoma in a child with multiple endocrine neoplasia 2B. Efficiency of medium-term treatment with vandetanib without thyroid surgery].
Segura D; Dupuis C; Chabre O; Piolat C; Durand C; Plantaz D
Arch Pediatr; 2016 Aug; 23(8):840-4. PubMed ID: 27345554
[TBL] [Abstract][Full Text] [Related]
5. Vandetanib in a Child Affected by Neurofibromatosis Type 1 and Medullary Thyroid Carcinoma with Both
Demir Gündoğan B; Sağcan F; Tuğ Bozdoğan S; Balcı Y; Tuncel Daloğlu F; Çağlar Çıtak E
J Clin Res Pediatr Endocrinol; 2021 Aug; 13(3):342-346. PubMed ID: 32702947
[TBL] [Abstract][Full Text] [Related]
6. [Vandetanib, in the management of patients with locally advanced or metastatic medullary thyroid carcinomas].
Chougnet CN; Schlumberger M; Leboulleux S; Baudin E
Bull Cancer; 2014 Sep; 101(9):891-5. PubMed ID: 25296193
[TBL] [Abstract][Full Text] [Related]
7. Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer.
Koehler VF; Adam P; Frank-Raue K; Raue F; Berg E; Hoster E; Allelein S; Schott M; Kroiss M; Spitzweg C
Thyroid; 2021 Mar; 31(3):459-469. PubMed ID: 32781914
[No Abstract] [Full Text] [Related]
8. Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma.
Fox E; Widemann BC; Chuk MK; Marcus L; Aikin A; Whitcomb PO; Merino MJ; Lodish M; Dombi E; Steinberg SM; Wells SA; Balis FM
Clin Cancer Res; 2013 Aug; 19(15):4239-48. PubMed ID: 23766359
[TBL] [Abstract][Full Text] [Related]
9. Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model.
Tappenden P; Carroll C; Hamilton J; Kaltenthaler E; Wong R; Wadsley J; Moss L; Balasubramanian S
Health Technol Assess; 2019 Feb; 23(8):1-144. PubMed ID: 30821231
[TBL] [Abstract][Full Text] [Related]
10. The safety and efficacy of vandetanib in the treatment of progressive medullary thyroid cancer.
Fallahi P; Ferrari SM; Baldini E; Biricotti M; Ulisse S; Materazzi G; Miccoli P; Antonelli A
Expert Rev Anticancer Ther; 2016 Nov; 16(11):1109-1118. PubMed ID: 27650489
[TBL] [Abstract][Full Text] [Related]
11. Phase I/II Trial of Vandetanib and Bortezomib in Adults with Locally Advanced or Metastatic Medullary Thyroid Cancer.
Del Rivero J; Edgerly M; Ward J; Madan RA; Balasubramaniam S; Fojo T; Gramza AW
Oncologist; 2019 Jan; 24(1):16-e14. PubMed ID: 30297385
[TBL] [Abstract][Full Text] [Related]
12. Vandetanib for the treatment of advanced medullary thyroid cancer outside a clinical trial: results from a French cohort.
Chougnet CN; Borget I; Leboulleux S; de la Fouchardiere C; Bonichon F; Criniere L; Niccoli P; Bardet S; Schneegans O; Zanetta S; Schvartz C; Drui D; Chauffert B; Rohmer V; Schlumberger M
Thyroid; 2015 Apr; 25(4):386-91. PubMed ID: 25627619
[TBL] [Abstract][Full Text] [Related]
13. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer.
Robinson BG; Paz-Ares L; Krebs A; Vasselli J; Haddad R
J Clin Endocrinol Metab; 2010 Jun; 95(6):2664-71. PubMed ID: 20371662
[TBL] [Abstract][Full Text] [Related]
14. Vandetanib for the treatment of medullary thyroid cancer.
Chau NG; Haddad RI
Clin Cancer Res; 2013 Feb; 19(3):524-9. PubMed ID: 23231950
[TBL] [Abstract][Full Text] [Related]
15. The safety of vandetanib for the treatment of thyroid cancer.
Tsang VH; Robinson BG; Learoyd DL
Expert Opin Drug Saf; 2016 Aug; 15(8):1107-13. PubMed ID: 27301016
[TBL] [Abstract][Full Text] [Related]
16. Systemic treatment and management approaches for medullary thyroid cancer.
Ernani V; Kumar M; Chen AY; Owonikoko TK
Cancer Treat Rev; 2016 Nov; 50():89-98. PubMed ID: 27664392
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib.
Kraft IL; Akshintala S; Zhu Y; Lei H; Derse-Anthony C; Dombi E; Steinberg SM; Lodish M; Waguespack SG; Kapustina O; Fox E; Balis FM; Merino MJ; Meltzer PS; Glod JW; Shern JF; Widemann BC
Clin Cancer Res; 2018 Feb; 24(4):753-765. PubMed ID: 29187393
[No Abstract] [Full Text] [Related]
18. Continued Discontinuation of TKI Treatment in Medullary Thyroid Carcinoma - Lessons From Individual Cases With Long-Term Follow-Up.
Brandenburg T; Tiedje V; Muchalla P; Theurer S; Weber F; Schmid KW; Dralle H; Führer D
Front Endocrinol (Lausanne); 2021; 12():718418. PubMed ID: 34659114
[TBL] [Abstract][Full Text] [Related]
19. Vandetanib: in medullary thyroid cancer.
Frampton JE
Drugs; 2012 Jul; 72(10):1423-36. PubMed ID: 22715896
[TBL] [Abstract][Full Text] [Related]
20. Vandetanib for the treatment of medullary thyroid carcinoma.
Cooper MR; Yi SY; Alghamdi W; Shaheen DJ; Steinberg M
Ann Pharmacother; 2014 Mar; 48(3):387-94. PubMed ID: 24259657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]